Arrowhead announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO-DUX4, the company’s investigational RNA interference, or RNAi, therapeutic being developed as a potential treatment for patients with facioscapulohumeral muscular dystrophy, or FSHD. ARO-DUX4 is the first clinical candidate utilizing Arrowhead’s proprietary Targeted RNAi Molecule platform to target disease associated genes in skeletal muscle.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARWR:
- Arrowhead management to meet with B. Riley
- B. Riley biotechnology analysts to hold an analyst/industry conference call
- Arrowhead files for regulatory clearance to initiate a Phase 1 study of ARO-SOD1
- Arrowhead presents updated data from Phase 2 SEQUOIA study
- Goldman Sachs Lifts S&P 500 Price Target; Here Are 2 High-Upside Stocks to Play the Bounce